The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Eicosapentaenoic acid (EPA) is a key anti-inflammatory/anti-aggregatory long-chain polyunsaturated omega-3 fatty acid. Conversely, the omega-6 fatty acid, arachidonic acid (AA) is a precursor to a number of pro-inflammatory/pro-aggregatory mediators. EPA acts competitively with AA for the key cyclooxygenase and lipoxygenase enzymes to form less inflammatory products. As a result, the EPA:AA ratio may be a marker of chronic inflammation, with a lower ratio corresponding to higher levels of inflammation. It is now well established that inflammation plays an important role in cardiovascular disease. This review examines the role of the EPA:AA ratio as a marker of cardiovascular disease and the relationship between changes in the ratio (mediated by EPA intake) and changes in cardiovascular risk. Epidemiological studies have shown that a lower EPA:AA ratio is associated with an increased risk of coronary artery disease, acute coronary syndrome, myocardial infarction, stroke, chronic heart failure, peripheral artery disease, and vascular disease. Increasing the EPA:AA ratio through treatment with purified EPA has been shown in clinical studies to be effective in primary and secondary prevention of coronary artery disease and reduces the risk of cardiovascular events following percutaneous coronary intervention. The EPA:AA ratio is a valuable predictor of cardiovascular risk. Results from ongoing clinical trials will help to define thresholds for EPA treatment associated with better clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525 · cited 6×
“EPA can act as a competitive inhibitor to AA for COX and LOX enzymes [7], resulting in compounds that have slightly different structures to AA-derived compounds,”
BackgroundInfluentialDistribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111
Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms
Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.935 · Cited by 950
Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers.
Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., Martin, A., Andres-Lacueva, C., Senin, U., & Guralnik, J. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1303 · Cited by 696 · cited 1×
“nists, and increased levels of anti-inflammatory markers, particularly transforming growth factor-β [88].”
BackgroundArachidonic acid: Physiological roles and potential health benefits – A review
Tallima, H., & El Ridi, R. (2018) · Journal of Advanced Research · doi:10.1016/j.jare.2017.11.004 · Cited by 671 · cited 1×
“A consideration of the entire AA metabolome is required to appreciate AA not as a risk factor, but rather a fatty acid important for normal health [11].”
BackgroundFish Consumption and Incidence of Stroke: A Meta-Analysis of Cohort Studies
He, K., Song, Y., Daviglus, M. L., Liu, K., Van Horn, L., Dyer, A. R., Goldbourt, U., & Greenland, P. (2004) · Stroke · doi:10.1161/01.str.0000130856.31468.47 · Cited by 371 · cited 1×
“94) for fish intake 2 to 4 times per week compared with <1 time per month [66].”
BackgroundBays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Cited by
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
Miyauchi, K., Iwata, H., Nishizaki, Y., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065520 · Cited by 114
Nutrition recommendations for bodybuilders in the off-season: a narrative review
Iraki, J., Fitschen, P., Espinar, S., & Helms, E. (2019) · Sports · doi:10.3390/sports7070154 · Cited by 67
Nishizaki, Y., Miyauchi, K., Iwata, H., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2022.11.008 · Cited by 40
Metadata
- Authors
- Nelson, J. R., & Raskin, S.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2019-05-07
- Volume
- 131
- Issue
- 4
- Pages
- 268-277
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2944526771
- Cited by
- 152
- References
- 17
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. https://app.cochat.ai/papers/10.1080/00325481.2019.1607414
- The paper
- Nelson, J. R., & Raskin, S. (2019). The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgraduate Medicine. https://doi.org/10.1080/00325481.2019.1607414
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.